Endogenex

Endogenex is developing a novel, minimally invasive endoscopic procedure using pulsed electric fields to treat Type 2 Diabetes.

 

www.endogenex.com
Plymouth, MN

CEO: Stacey Pugh
Arboretum Lead: Tom Shehab, MD

IN THE NEWS
July 8, 2026 in Endogenex, Home Page, News Page

Endogenex Announces Full Enrollment of the ReCET Clinical Study

Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET Clinical Study has reached full enrollment. A total of…
Read More
March 25, 2026 in Endogenex, Home Page, News Page

Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval

Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes.
Read More